drug_type
RELEVANT_DRUG
intervention_type
Biological (CAR T-cell therapy)
drug_description
Autologous, genetically engineered CAR T-cell therapy targeting CLDN18.2; engineered T cells bind CLDN18.2 on tumor cells to activate T-cell proliferation, cytokine release, and cytotoxic killing.
nci_thesaurus_concept_id
C201144
nci_thesaurus_definition
A preparation of T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18), with potential immunostimulating and antineoplastic activities. Upon administration, anti-CLDN18.2 CAR-T cells AZD6422 specifically recognize and bind to CLDN18.2-expressing tumor cells. This may result in a specific cytotoxic T-lymphocyte (CTL)-mediated killing of CLDN18.2-expressing tumor cells. CLDN18.2, a tight junction protein and stomach-specific isoform of claudin-18, is overexpressed on a variety of tumor cells, but its expression in healthy tissues is strictly confined to short-lived differentiated epithelial cells of the gastric mucosa.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express a chimeric antigen receptor targeting CLDN18.2. Upon binding CLDN18.2 on tumor cells, the CAR activates T cells independently of native TCR/MHC, driving T‑cell expansion, cytokine release, and cytotoxic killing of CLDN18.2‑expressing tumor cells.
drug_name
AZD6422
nct_id_drug_ref
NCT05981235